These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3793959)

  • 1. Parkinson's disease: follow-up after "drug holiday".
    Feldman RG; Kaye JA; Lannon MC
    J Clin Pharmacol; 1986; 26(8):662-7. PubMed ID: 3793959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of L-dopa holiday in the long-term management of Parkinson's disease.
    Kaye JA; Feldman RG
    Clin Neuropharmacol; 1986; 9(1):1-13. PubMed ID: 3548951
    [No Abstract]   [Full Text] [Related]  

  • 3. [The results of drug holiday in Parkinson's disease].
    Martínez F; Castillo J; Castro A; Lema M; Noya M
    Neurologia; 1992 Nov; 7(9):254-9. PubMed ID: 1445710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson's disease.
    Corona T; Rivera C; Otero E; Stopp L
    Clin Neuropharmacol; 1995 Aug; 18(4):325-32. PubMed ID: 8665545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reappraisal of temporary levodopa withdrawal ("drug holiday") in Parkinson's disease.
    Mayeux R; Stern Y; Mulvey K; Cote L
    N Engl J Med; 1985 Sep; 313(12):724-8. PubMed ID: 4033697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Drug holidays' in the treatment of Parkinson's disease. A brief review.
    Friedman JH
    Arch Intern Med; 1985 May; 145(5):913-5. PubMed ID: 3888135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study.
    Poewe WH; Lees AJ; Stern GM
    Neurology; 1986 Nov; 36(11):1528-30. PubMed ID: 3762973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complications of chronic levodopa therapy: long-term efficacy of drug holiday.
    Koller WC; Weiner WJ; Perlik S; Nausieda PA; Goetz CG; Klawans HL
    Neurology; 1981 Apr; 31(4):473-6. PubMed ID: 7194441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug holiday and management of Parkinson disease.
    Weiner WJ; Koller WC; Perlik S; Nausieda PA; Klawans HL
    Neurology; 1980 Dec; 30(12):1257-61. PubMed ID: 7192805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Usefulness of drug holiday in patients with Parkinson's disease of more than 5 years of development].
    Corona T; Rivera Nava C; Reyes Báez B; Carbajal A
    Rev Invest Clin; 1991; 43(4):334-7. PubMed ID: 1798867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
    Koziorowski D; Friedman A
    Mov Disord; 2007 May; 22(7):1033-6. PubMed ID: 17370308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up.
    Lees AJ; Stern GM
    Adv Neurol; 1983; 37():9-15. PubMed ID: 6858781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations.
    Poewe WH; Lees AJ; Stern GM
    Clin Neuropharmacol; 1986; 9(5):430-9. PubMed ID: 3768865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is L-DOPA drug holiday useful?
    Direnfeld LK; Feldman RG; Alexander MP; Kelly-Hayes M
    Neurology; 1980 Jul; 30(7 Pt 1):785-8. PubMed ID: 7190248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.